Research Papers:
KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2705 views | HTML 4691 views | ?
Abstract
Georgios Pampalakis1, Vasia-Samantha Sykioti2, Methodios Ximerakis2, Ioanna Stefanakou-Kalakou1, Ronald Melki3, Kostas Vekrellis2, Georgia Sotiropoulou1,2
1Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Athens, Greece
2Center for Neurosciences, Biomedical Research Foundation, Academy of Athens, Athens, Greece
3Paris-Saclay Institute of Neuroscience, Centre National de la Recherche Scientifique, Gif-Sur-Yvette, France
Correspondence to:
Georgia Sotiropoulou, email: [email protected]
Kostas Vekrellis, email: [email protected]
Keywords: KLK6, α-synuclein, degradomics, metalloproteases, in vitro substrates
Received: July 28, 2016 Accepted: October 28, 2016 Published: November 10, 2016
ABSTRACT
KLK6 is a serine protease highly expressed in the nervous system. In synucleinopathies, including Parkinson disease, the levels of KLK6 inversely correlate with α-synuclein in CSF. Recently, we suggested that recombinant KLK6 mediates the degradation of extracellular α-synuclein directly and via a proteolytic cascade that involves unidentified metalloproteinase(s). Here, we show that recombinant and naturally secreted KLK6 can readily cleave α-synuclein fibrils that have the potential for cell-to-cell propagation in “a prion-like mechanism”. Importantly, KLK6-deficient primary cortical neurons have increased ability for α-synuclein fibril uptake. We also demonstrate that KLK6 activates proMMP2, which in turn can cleave α-synuclein. The repertoire of proteases activated by KLK6 in a neuronal environment was analyzed by degradomic profiling, which also identified ADAMTS19 and showed that KLK6 has a limited number of substrates indicating specific biological functions such as the regulation of α-synuclein turnover. We generated adenoviral vectors for KLK6 delivery and demonstrated that the levels of extracellular α-synuclein can be reduced by neuronally secreted KLK6. Our findings open the possibility to exploit KLK6 as a novel therapeutic target for Parkinson disease and other synucleinopathies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13264